Zymeworks (NASDAQ:ZYME) Given New $32.00 Price Target at Truist Financial

Zymeworks (NASDAQ:ZYME) had its target price raised by Truist Financial from $31.00 to $32.00 in a research report report published on Friday morning, Marketbeat Ratings reports. Truist Financial currently has a buy rating on the stock.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a report on Friday, July 17th. HC Wainwright increased their price objective on shares of Zymeworks from $46.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup restated a “buy” rating on shares of Zymeworks in a research report on Tuesday, June 30th. Finally, Wells Fargo & Company boosted their target price on shares of Zymeworks from $37.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $38.22.

Zymeworks Stock Up 1.8%

Shares of ZYME stock opened at $23.54 on Friday. The business has a fifty day simple moving average of $23.99 and a 200 day simple moving average of $24.45. The company has a market cap of $1.72 billion, a P/E ratio of -11.65 and a beta of 1.15. Zymeworks has a twelve month low of $11.51 and a twelve month high of $29.75.

Zymeworks (NASDAQ:ZYME) last released its earnings results on Thursday, August 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). The business had revenue of $4.59 million during the quarter, compared to the consensus estimate of $4.54 million. Zymeworks had a negative net margin of 405.31% and a negative return on equity of 60.02%. The business’s revenue was down 90.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.03 EPS. As a group, equities research analysts anticipate that Zymeworks will post 1.25 earnings per share for the current fiscal year.

Zymeworks declared that its Board of Directors has initiated a share repurchase plan on Thursday, May 14th that allows the company to repurchase $125.00 million in shares. This repurchase authorization allows the company to buy up to 7% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On Zymeworks

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd acquired a new position in shares of Zymeworks during the fourth quarter worth $37,000. State of Wyoming bought a new position in Zymeworks during the 2nd quarter worth $73,000. Quarry LP bought a new position in Zymeworks during the 3rd quarter worth $50,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Zymeworks by 25.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,637 shares of the company’s stock worth $96,000 after buying an additional 731 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in shares of Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock valued at $62,000 after buying an additional 1,131 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Key Zymeworks News

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Truist raises target and maintains a Buy rating: Truist Financial lifted its price target from $31 to $32, implying substantial upside from recent trading levels. The firm’s continued Buy recommendation may support investor confidence. Benzinga article
• Positive Sentiment: Analysts remain broadly bullish: HC Wainwright reiterated its Buy rating and $51 price target, while a separate brokerage report cited an average price target of $37.33. These targets suggest analysts see meaningful long-term value in Zymeworks despite near-term losses. Average price target article
• Neutral Sentiment: Revenue exceeded expectations: Zymeworks reported quarterly revenue of $4.59 million, ahead of the $3.81 million consensus estimate. However, the company remains unprofitable, limiting the positive impact of the revenue beat. Zacks earnings article
• Negative Sentiment: Quarterly loss was wider than expected: Zymeworks posted a loss of $0.62 per share, missing estimates for a $0.56–$0.57 loss and reversing year-earlier earnings of $0.03 per share. Revenue also declined 90.6% year over year, while the company reported a negative net margin and return on equity. Zymeworks earnings release
• Negative Sentiment: HC Wainwright cut earnings forecasts: The firm reduced its FY2026 EPS estimate from $1.00 to $0.36 and lowered its Q2 and Q4 forecasts to losses of $0.58 and $0.54 per share, respectively. It also trimmed its Q3 estimate to $2.09 from $2.17, signaling weaker near-term earnings expectations.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.